Allosteric IGF-1R inhibitors

ACS Medicinal Chemistry Letters

Volumn 1, Issue 5, 2010, Pages 199-203

  Heinrich, Timo ^a   Grädler, Ulrich ^a   Böttcher, Henning ^a   Blaukat, Andree ^a   Shutes, Adam ^b  

^a Merck Serono GmbH   (Germany)

^b EMD SERONO INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 CYANO 1H INDOLE 7 CARBOXYLIC ACID [1 [4 (5 CYANO 1H INDOL 3 YL)BUTYL]PIPERIDIN 4 YL]AMIDE; INSULIN LIKE GROWTH FACTOR 1 RECEPTOR INHIBITOR; INSULIN RECEPTOR; RECEPTOR BLOCKING AGENT; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG;

ALLOSTERISM; ARTICLE; CRYSTAL STRUCTURE; DRUG BINDING SITE; DRUG POTENCY; DRUG SELECTIVITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

EID: 77956136788     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml100044h     Document Type: Article

References (30)

1. Ciardiello, F.; Tortora, G. Anti-epidermal growth factor receptor drugs in cancer therapy Expert Opin. Invest. Drugs 2002, 11, 755-768
2. Renhowe, P. A. Inhibitors of growth factor receptor kinase-dependent signaling pathways in anticancer chemotherapy - Clinical progress Curr. Opin. Drug Discovery Dev. 2002, 5, 214-224
3. Kiselyov, A.; Balakin, K. V.; Tkachenko, S. E.; Savchuk, N. P. Recent progress in development of non-ATP competitive small-molecule inhibitors of protein kinases Mini-Rev. Med. Chem. 2006, 6, 711-717
4. Dumas, J.; Sibley, R.; Riedl, B.; Monahan, M. K.; Lee, W.; Lowinger, T. B.; Redman, A. M.; Johnson, J. S.; Kingery-Wood, J.; Scott, W. J.; Smith, R. A.; Bobko, M.; Schoenleber, R.; Ranges, G. E.; Housley, T. J.; Bhargava, A.; Wilhelm, S. M.; Shrikhande, A. Discovery of a new class of p38 kinase inhibitors Bioorg. Med. Chem. Lett. 2000, 10, 2047-2050
5. Yong, H.-Y.; Koh, M.-S.; Moon, A. The p38 MAPK inhibitors for the treatment of inflammatory diseases and cancer Expert Opin. Invest. Drugs 2009, 18, 1893-1905
6. Gumireddy, K.; Reddy, M.V. R.; Cosenza, S. C.; Boominathan, R.; Baker, S. J.; Papathi, N.; Jiang, J.; Holland, J.; Reddy, E. P. ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent Cancer Cell 2005, 7, 275-286
7. Martinez, A.; Alonso, M.; Castro, A.; Pérez, C.; Moreno, F. J. First non-ATP competitive glycogen synthase kinase 3 ? (GSK-3?) inhibitors: Thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease J. Med. Chem. 2002, 45, 1292-1299
8. Ghayad, S. E; Cohen, P. A. Inhibitors of the PI3K/ Akt/mTOR pathway: New hope for breast cancer patients Recent Pat. Anti-Cancer Drug Discovery 2010, 5, 29-57
9. Austin, D.; Shivaani, K. Targeting mitogen-activated protein kinase kinase (MEK) in solid tumors Targeted Oncol. 2009, 4, 267-273
10. Denley, A.; Cosgrove, L. J.; Booker, G. W.; Wallace, J. C.; Forbes, B. E. Molecular interactions of the IGF system Cytokine Growth Factor Rev. 2005, 16, 421-439
11. Frasca, F.; Pandini, G.; Scalia, P.; Sciacca, L.; Mineo, R.; Costantino, A.; Goldfine, I. D.; Belfiore, A.; Vigneri, R. Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells Mol. Cell. Biol. 1999, 19, 3278-3288
12. Wang, Y.; Sun, Y. Insulin-like growth factor receptor-1 as an anti-cancer target: Blocking transformation and inducing apoptosis Curr. Cancer Drug Targets 2002, 2, 191-207
13. Pollak, M. N.; Eisenberg, P.; Karp, D.; Cohen, R.; Kreisman, H.; Adjei, A.; Langer, C.; Melvin, C.; Yin, D.; Gualberto, A. Safety and tolerability of the anti-IGF-I receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in patients with advanced solid tumors AACR Annual Meeting 2007, 98th; April 17; Absract LB-343.
14. Kusada, Y.; Fujita-Yamaguchi, Y. An overview of currently available anti- insulin-like growth factor I receptor antibodies BioSci. Trends 2007, 1, 128-133
15. Atzori, F.; Traina, T. A.; Ionta, M. T.; Massidda, B. Targeting insulin-like growth factor type 1 receptor in cancer therapy Targeted Oncol. 2009, 4, 255-266
16. Weroha, S. J.; Haluska, P. IGF-1 receptor inhibitors in clinical trials-early lessons J. Mammary Gland Biol. Neoplasia 2008, 13, 471-483
17. Ullrich, A.; Gray, A.; Tam, A. W.; Yang-Feng, T.; Tsubokawa, M.; Collins, C.; Henzel, W.; Le Bon, T.; Kathuria, S.; Chen, E.; Jacobs, S.; Francke, U.; Ramachandran, J.; Fujita-Yamaguchi, Y. Insulin-like growth factor I receptor primary structure: Comparison with insulin receptor suggests structural determinants that define functional specificity EMBO J. 1986, 5, 2503-2512
18. IR inhibition would induce diabetes in treated patients sooner or later, what is not compatible with the strategy to deal with cancer as with blood preasure in a live long medication context.
19. Schindler, T.; Bornmann, W.; Pellicena, P.; Miller, W. T.; Clarkson, B.; Kuriyan, J. Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase Science 2000, 289, 1938-1942
20. Engh, R. A.; Bossemeyer, D. The protein kinase activity modulation sites: Mechanisms for cellular regulation - Targets for therapeutic intervention Adv. Enzyme Regul. 2001, 41, 121-149
21. Munshi, S.; Kornienko, M.; Hall, D. L.; Reid, J. C.; Waxman, L.; Stirdivant, S. M.; Darke, P. L.; Kuo, L. C. Crystal structure of the apo, unactivated insulin-like growth factor-1 receptor kinase. Implication for inhibitor specificity J. Biol. Chem. 2002, 277, 38797-38802
22. Li, W.; Favelyukis, S.; Yang, J.; Zeng, Y.; Yu, J.; Gangjee, A.; Miller, W. T. Inhibition of insulin-like growth factor I receptor autophosphorylation by novel 6?5 ring-fused compounds Biochem. Pharmacol. 2004, 68, 145-154
23. Heinrich, T.; Boettcher, H.; Gericke, R.; Bartoszyk, G. D.; Anzali, S.; Seyfried, C. A.; Greiner, H. E.; van Amsterdam, C. Synthesis and structure?activity relationship in a class of indolebutylpiperazines as dual 5-HT1A receptor agonists and serotonin reuptake inhibitors J. Med. Chem. 2004, 47, 4684-4692
24. A lot of different derivatives with modified indole cores and butyl chains were prepared. Unfortunately, all of these derivatizations did not result in any improvement, so we decided not to show these compounds explicitly.
25. Crassier, H.; Boettcher, H.; Eckert, U.; Bathe, A.; Emmert, S. Procedure for the production of (3-cyano-1H-indol-7-yl)-[4-(4-fluorophenylethyl)piperazin- 1-yl]methanone and its salts. DE 10102944, 2002.
26. See the Supporting Information.
27. Munshi, S.; Hall, D. L.; Kornienko, M.; Darke, P. L.; Kuo, L. C. Structure of apo, unactivated insulin-like growth factor-1 receptor kinase at 1.5 Å resolution Acta Crystallogr., Sect. D: Biol. Crystallogr. 2003, D59, 1725-1730
28. Wittman, M. D.; Balasubramanian, B.; Stoffan, K.; Velaparthi, U.; Liu, P.; Krishnanathan, S.; Carboni, J.; Li, A.; Greer, A.; Attar, R.; Gottardis, M.; Chang, C.; Jacobson, B.; Sun, Y.; Hansel, S.; Zoeckler, M.; Vyas, D. M. Novel 1H-(benzimidazol-2-yl)-1H-pyridin-2-one inhibitors of insulin-like growth factor I (IGF-1R) kinase Bioorg. Med. Chem. Lett. 2007, 17, 974-977
29. Warshamana-Greene, G. S.; Litz, J.; Buchdunger, E.; Garcia-Echeverria, C.; Hofmann, F.; Krystal, G. W. The insulin-like growth factor-I receptor kinase inhibitor, NVP-ADW742, sensitizes small cell lung cancer cell lines to the effects of chemotherapy Clin. Cancer Res. 2005, 11, 1563-1571
30. Unpublished results.